Company research
RenovoRx, Inc.
CIK 1574094Updated Sep 24, 2026
SecurityRNXT · NASDAQ · equity
RNXT price & chart
Loading TradingView…
NASDAQ:RNXT on TradingView ↗About the company
RenovoRx, Inc. (Nasdaq: RNXT) is a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, U.S. Food and Drug Administration (FDA)-cleared local drug-delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor, while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and its mission is to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents.
In the news
RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement ↗
Recent filings
4 filing
Other Events
Items 8.01
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Financial Statements and Exhibits
Items 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 8,095,000Source | 8,118,000Source | 1,466,000Source | 7,265,000Source |
| Property, Plant and Equipment, NetUSD | 12,000Source | 12,000Source | — | — |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 7,024,000Source | 7,154,000Source | 1,173,000Source | 4,391,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 139,000Source | 43,000Source | — | — |
| Inventory, NetUSD | 189,000Source | — | — | — |
| Assets, CurrentUSD | 7,893,000Source | 7,828,000Source | — | 7,265,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | — | — | 192,000Source | 825,000Source |
| Operating Lease, Right-of-Use AssetUSD | 190,000Source | 278,000Source | — | — |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 2,673,000Source | 3,640,000Source | 4,466,000Source | 1,102,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | — | — | — |
| Common Stock, Value, IssuedUSD | 4,000Source | 2,000Source | 1,000Source | 1,000Source |
| Retained Earnings (Accumulated Deficit)USD | -61,387,000Source | -50,219,000Source | -41,405,000Source | -31,173,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | — | — | — | 17,000Source |
| Stockholders' Equity Attributable to ParentUSD | 5,422,000Source | 4,478,000Source | -3,000,000Source | 6,163,000Source |
| Additional Paid in Capital, Common StockUSD | 66,805,000Source | 54,695,000Source | 38,404,000Source | 37,318,000Source |
| Liabilities and EquityUSD | 8,095,000Source | 8,118,000Source | 1,466,000Source | 7,265,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 1,962,000Source | 1,909,000Source | 1,175,000Source | — |
| Operating Lease, Liability, CurrentUSD | 105,000Source | 66,000Source | — | — |
| Accounts Payable, CurrentUSD | 799,000Source | 586,000Source | 561,000Source | 534,000Source |
| Operating Lease, Liability, NoncurrentUSD | 107,000Source | 212,000Source | — | — |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 1,163,000Source | 1,323,000Source | 614,000Source | 568,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | 6,400,000Source |
| Deferred Tax Liabilities, NetUSD | 49,000Source | 79,000Source | — | 18,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation and amortization | — | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 1,267,000Source | 1,174,000Source | 1,078,000Source | 644,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in InventoriesUSD | 189,000Source | — | — | — |
| Increase (Decrease) in Accounts PayableUSD | 213,000Source | 25,000Source | 27,000Source | 9,000Source |
| Deferred Income Tax Expense (Benefit)USD | 0Source | — | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -10,973,000Source | -9,125,000Source | -10,258,000Source | -8,811,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -2,000Source | -12,000Source | 2,032,000Source | -2,032,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 2,000Source | 12,000Source | — | — |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 10,845,000Source | 15,118,000Source | 5,008,000Source | 42,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -130,000Source | 5,981,000Source | -3,218,000Source | -10,801,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 16,000Source | 21,000Source | — | — |
| Income Taxes Paid, NetUSD | 1,000Source | 2,000Source | — | — |
| Additional Financial Items | ||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | 6,400,000Source |
| DepreciationUSD | 2,000Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | 5,729,000Source | 5,649,000Source |
| Income Tax Expense (Benefit)USD | 2,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -11,168,000Source | -8,814,000Source | -10,232,000Source | -9,889,000Source |
| Nonoperating Income (Expense)USD | 1,342,000Source | 2,156,000Source | 1,164,000Source | 61,000Source |
| Operating ExpensesUSD | 13,306,000Source | 11,013,000Source | 11,396,000Source | 9,950,000Source |
| Operating Lease, ExpenseUSD | — | — | 75,000Source | 72,000Source |
| Other Nonoperating Income (Expense)USD | — | — | — | 4,000Source |
| Proceeds from Issuance of Common StockUSD | 12,102,000Source | 15,016,000Source | 5,000,000Source | — |
| Proceeds from Stock Options ExercisedUSD | 17,000Source | 69,000Source | 8,000Source | 42,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 1,123,000Source | 43,000Source | — | — |
| Cost of Goods and Services Sold | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | 7,037,000Source | 4,988,000Source | — | — |
| Operating Income (Loss)USD | -12,510,000Source | -10,970,000Source | -11,396,000Source | -9,950,000Source |
| Other Nonoperating Income (Expense)USD | — | — | — | 4,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -11,167,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | 2,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -11,168,000Source | -8,814,000Source | -10,232,000Source | -9,889,000Source |
| Earnings Per Share, BasicUSD per share | -0.32Source | -0.4Source | -0.99Source | -1.09Source |
| Earnings Per Share, DilutedUSD per share | -0.32Source | -0.4Source | -0.99Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 35,333,127Source | 22,271,163Source | 10,290,667Source | 9,051,726Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 35,333,127Source | 22,271,163Source | 10,290,667Source | — |
| Additional Financial Items | ||||
| Current Income Tax Expense (Benefit)USD | 2,450,000Source | — | — | — |
| Depreciation, Depletion and Amortization, NonproductionUSD | 2,000,000Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | 5,729,000Source | 5,649,000Source |
| Gross ProfitUSD | 796,000Source | 43,000Source | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -11,167,000Source | — | — | — |
| Interest Income (Expense), Nonoperating, NetUSD | 427,000Source | 384,000Source | 108,000Source | 57,000Source |
| Nonoperating Income (Expense)USD | 1,342,000Source | 2,156,000Source | 1,164,000Source | 61,000Source |
| Operating ExpensesUSD | 13,306,000Source | 11,013,000Source | 11,396,000Source | 9,950,000Source |
| Operating Lease, ExpenseUSD | — | — | 75,000Source | 72,000Source |
| Research and Development ExpenseUSD | 6,269,000Source | 6,025,000Source | 5,667,000Source | 4,301,000Source |
Filing attachments
rnxt-ex99_1.htm · 8-K/A · 2026-08-13
EX-99.1 2 rnxt-ex99_1.htm EX-99.1 EX-99.1 RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth Increases 2026 Annual Revenue Guidance to a Range of $3.75M to $4.25M First Treatment Delivered with RenovoCath® in Patient with Sarcoma in Clinical Setting, Marking Expansion of Device to Other Solid Tumors Phase III TIGeR-PaC Trial Reaches Full Enrollment; Completion of Trial Expected in First Half 2027 wit…
Read attachment ↗rnxt-ex99_1.htm · 8-K · 2026-08-12
EX-99.1 2 rnxt-ex99_1.htm EX-99.1 EX-99.1 RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth Increases 2026 Annual Revenue Guidance to a Range of $3.75M to $4.25M First Treatment Delivered with RenovoCath® in Patient with Sarcoma in Clinical Setting, Marking Expansion of Device to Other Solid Tumors Phase III TIGeR-PaC Trial Reaches Full Enrollment; Completion of Trial Expected in First Half 2027 wit…
Read attachment ↗ex99-1.htm · 8-K · 2026-08-04
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 RenovoRx to Highlight TAMP™ Platform at JonesTrading Virtual Key Opinion Leader Webinar on the Evolving Pancreatic Cancer Landscape, August 13th MOUNTAIN VIEW, Calif., August 4, 2026 - RenovoRx, Inc. (“RenovoRx” or “the Company”) ( Nasdaq: RNXT ), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced it will participate in a JonesTradi…
Read attachment ↗rnxt-ex99_1.htm · 8-K · 2026-05-14
EX-99.1 2 rnxt-ex99_1.htm EX-99.1 EX-99.1 RenovoRx Reports Record First Quarter 2026: Increasing Revenue by 136% Quarter-over-Quarter Q1 2026 Revenue of $563,000 Totals Over 50% of Full Year 2025 Total Revenue Active Commercial Cancer Center Customers Expand to 16 with Growing Sales Pipeline, Accelerating Adoption of the TAMP™ Therapy Platform Enabled by the RenovoCath® Device Phase III TIGeR-PaC Trial Advances Toward Completion with Full Enrollment Expected in June 2026 Ended First Qu…
Read attachment ↗ex99-1.htm · 8-K · 2026-03-30
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update RenovoCath® Generates $1.1 Million in 2025 Revenue in First Full Year of Commercialization Phase III TIGeR-PaC Trial on Track for Enrollment Completion by the Middle of 2026, and Final Data Anticipated in 2027 With $13 Million on Hand, Company has the Funding, Business Plan, Leadership, and Infrastructure to Drive Growth and Shareholder Value Management to Host Confer…
Read attachment ↗ex4-1.htm · 8-K · 2026-03-23
EX-4.1 2 ex4-1.htm EX-4.1 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE …
Read attachment ↗